Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07500506 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine
A Phase 3 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,712
- Enrollment target
NCT07500506 is a Phase 3 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 1,712 participants.
The verdict
NCT07500506, a Phase 3 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,712 participants
- Enrollment target
Study Summary
The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and older, * have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4. * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners. * are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine. All participants in this study will receive a total of 1 dose through a shot in the upper arm, either VLA15 or saline shot (saltwater). The study will compare the experiences of people receiving the study vaccine or saltwater shot. Participants will take part in this study for about 12 months. During this time, they will have 4 planned clinic visits. The clinic visits may include having a health check, giving a small amount of blood and getting the study vaccine or saltwater as a shot at the first visit.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VLA15
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,712 participants |
| Start Date | 2026-04-08 |
| Est. Completion | 2026-12-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07500506
The ClinicalTrials.gov registry entry for NCT07500506 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,712 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07500506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07500506 about?
NCT07500506 is a clinical study titled "A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine". The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and older, * have alrea...
What is the current status of trial NCT07500506?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,712 participants. The study started on 2026-04-08. Estimated completion is 2026-12-04.
What interventions are being tested in trial NCT07500506?
The interventions under investigation include: Placebo (BIOLOGICAL), VLA15 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07500506?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.